Blood cancers

Episode 2: The changing therapeutic landscape for R/R CLL, with Dr Phillip Thompson

Tuesday, 17 Dec 2019


In the second part of this podcast, haematologist and clinical researcher Dr Phillip Thompson talks about the rapidly evolving area of treatment for relapsed/refractory CLL after chemo-immunotherapy.

Dr Thompson  says it is important to re-evaluate a person’s genomic characteristics after a relapse and the overall approach is to use novel agents rather than repeat chemo-immunotherapy.

He describes the latest evidence of survival benefits with novel agents in R/R CLL.  Dr Thompson also talks about two exciting new lines of research in Richter’s transformation where spectacular response rates have been achieved with some agents.

Part 1 of the podcast is on treatment in front-line CLL

PLEASE REVIEW PRODUCT INFORMATION BEFORE PRESCRIBING (available from www.janssen.com.au/imbruvica_PI).

Already a member?

Login to keep reading.

OR
Email me a login link
logo

© 2022 the limbic